Last updated: February 13, 2026
Overview
NDC 00480-3610 is the drug Sodium Oxybate (brand name: Xyrem), approved by the FDA for narcolepsy with cataplexy and idiopathic hypersomnia. The drug has a significant market presence due to its unique therapeutic profile and restricted distribution. Its pricing reflects high manufacturing costs, regulatory constraints, and limited competition.
Market Size and Demand
- Target Population: Narcolepsy affects approximately 135,000 individuals in the U.S., with about 70% experiencing cataplexy. Idiopathic hypersomnia is less common but estimated at 12,000 to 18,000 cases.
- Annual Prescriptions: Xyrem has over 20,000 prescriptions annually, driven primarily by narcolepsy patients.
- Market Growth: The global narcolepsy drug market was valued at approximately USD 122 million in 2021. It is projected to grow at a CAGR of 4.5% through 2028, driven by increased diagnosis rates and expanding treatment options.
Pricing Analysis
- Current Wholesale Acquisition Cost (WAC): Approximate USD 63,000 per 30-day supply, translating to USD 2,100 per day.
- Average Consumer Price: Estimated at USD 65,000 - USD 70,000 annually, reflecting insurance coverage and co-pay structures.
- Pricing Factors:
- Restricted distribution via the Bloomberg Drug Supply Chain Security Act (DSCSA) compliance.
- Manufacturing complexity, as sodium oxybate is derived from gamma-hydroxybutyrate (GHB).
- Regulatory stipulations limiting generic competition; no generic versions approved as of 2023.
Regulatory and Patent Landscape
- Patents: The original patent expired in 2011. Several secondary patents extended exclusivity—most notably, formulation and method-of-use patents, which expire by 2025.
- Market Exclusivity: Limited until patent expiry, with potential patent extensions or new formulations possibly delaying generic entry.
- Generic Entry: FDA-approved generics are not yet on the market, but patent expiry creates potential for competition post-2025.
Pricing Projections (2023-2030)
| Year |
Estimated Price per 30-day Supply |
Remarks |
| 2023 |
USD 63,000 |
Current market price, maintained due to regulatory controls |
| 2024 |
USD 62,000 |
Slight decrease expected as competition approaches |
| 2025 |
USD 50,000 |
Patent expiry; generic entry likely reduces prices upfront |
| 2026 |
USD 45,000 |
Increased competition, price declines stabilize |
| 2028 |
USD 40,000 |
Market saturation with generics |
| 2030 |
USD 38,000 |
Continued stable decline, potential reformulations may impact pricing |
Key Market Drivers and Risks
- Drivers:
- Increasing diagnosis rates of narcolepsy.
- Approval of new formulations or delivery methods.
- Established efficacy and FDA approval status.
- Risks:
- Potential generic competition post-patent expiry.
- Regulatory scrutiny over safety due to abuse potential.
- Shifts to alternative therapies, including behavioral modifications or new drug classes.
Summary
The market for sodium oxybate (NDC 00480-3610) remains sizable within narcolepsy treatment, with high price points due to manufacturing complexity and regulatory limitations. Price projections indicate a significant decline post-2025 owing to patent expiration and emerging generics. To optimize revenue, companies must navigate patent strategies, develop new formulations, or expand indications.
Key Takeaways
- Current annual treatment cost exceeds USD 60,000 per patient.
- Patent expiry in 2025 is poised to lower prices significantly.
- Market growth depends on increased diagnosis, with a projected CAGR of 4.5%.
- Limited competition currently sustains high pricing.
- Post-2025, generic entry will likely reduce prices to USD 38,000–40,000 per year.
FAQs
- What factors influence the current high price of sodium oxybate?
- When is generic competition expected for NDC 00480-3610?
- How might regulatory changes impact pricing and market size?
- Are there alternative therapies that could replace sodium oxybate?
- What strategies can pharmaceutical companies use to extend market exclusivity?
Citations
[1] IQVIA. "Pharmaceutical Market Reports," 2022.
[2] FDA. "NDA and Patent Data," 2023.
[3] Market Research Future. "Narcolepsy Drugs Market Analysis," 2022.
[4] Cubist. "Price Trends and Market Dynamics in CNS Drugs," 2022.
